Frankfurt
13.07.26 | 08:08
0,060 Euro
+8,70 % +0,005
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Isofol Medical AB: Isofol initiates last dose cohort in ongoing phase Ib study with arfolitixorin | 237 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, July 8, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has completed the third dose level in the dose-escalation part of the phase... ► Artikel lesen | |
| 19.05. | Isofol Medical AB: Bulletin from annual general meeting in Isofol Medical AB (publ) held on 19 May, 2026 | 404 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, May 19, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) (the "Company") held its annual general meeting (the "AGM") today. The following resolutions, in principle, were... ► Artikel lesen | |
| 19.05. | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January - March 2026 | 152 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, May 19, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), ("Isofol" or the "Company"), announced today that the company's interim report for January - March 2026 is now... ► Artikel lesen | |
| ISOFOL MEDICAL Aktie jetzt für 0€ handeln | |||||
| 15.04. | Isofol Medical AB: Isofol optimizes the design of its phase Ib/II study following new regulatory approval | 455 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, April 15, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that the German regulatory authority BfArM has approved an optimized design for the company's... ► Artikel lesen | |
| 18.03. | Isofol Medical AB: Isofol secures license rights for arfolitixorin in autism | 774 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, March 18, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that the company has expanded its global exclusive license agreement for arfolitixorin to also... ► Artikel lesen | |
| 11.03. | Isofol Medical AB: Isofol receives top guarantee commitment and letters of intent corresponding to 42 percent of upcoming warrant exercise | 349 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, 11 March 2026 - Isofol Medical AB ("Isofol" or the "Company") announces today that the Company has received a top guarantee commitment from existing shareholder Solasia Pharma K.K.... ► Artikel lesen | |
| 24.02. | Isofol Medical AB: Isofol provides update on the ongoing phase Ib/II clinical study of arfolitixorin | 432 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, February 24, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today provides an update on the company's ongoing phase Ib/II clinical study of arfolitixorin, which is initially... ► Artikel lesen | |
| 18.02. | Isofol Medical AB: Isofol Medical AB (publ) publishes year-end report, January - December 2025 | 189 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, February 18, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), ("Isofol" or the "Company"), announced today that the company's year-end report for January - December 2025... ► Artikel lesen | |
| 13.11.25 | Isofol Medical AB: European Patent Office intends to grant a new patent for Isofol's arfolitixorin | 399 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, November 13 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the European Patent Office (EPO) has issued an Intention to Grant notice regarding a... ► Artikel lesen | |
| 12.11.25 | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-September 2025 | 256 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, November 12, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), ("Isofol" or the "Company"), announced today that the company's interim report for January-September 2025... ► Artikel lesen | |
| 30.09.25 | Isofol Medical AB: Isofol's clinical study with arfolitixorin reaches another important milestone | 457 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, September 30, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has successfully completed the second dose level in the dose escalating... ► Artikel lesen | |
| 26.09.25 | Isofol Medical AB: Isofol completes transfer of shares to Solasia Pharma following a successful rights issue | 334 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, September 26, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the transfer of the shares subscribed by the Japanese collaboration partner Solasia... ► Artikel lesen | |
| 26.08.25 | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-June 2025 | 261 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, August 26, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January-June 2025 is now available, in Swedish, on the... ► Artikel lesen | |
| 16.07.25 | Isofol Medical AB: Isofol successfully completes pre-IND meeting with the FDA for arfolitixorin | 351 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, July 16, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has successfully completed a pre-IND meeting with the U.S. Food and Drug Administration... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,248 | +1,54 % | Valneva mit Rekordsignal: 2,5% Plus und das könnte erst der Anfang sein - Was ich konkret unternommen habe! | ||
| INTELLIA THERAPEUTICS | 11,780 | -5,46 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| SIRONA BIOCHEM | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 24.04.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 24.04.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 24.04.2026.ISIN NameCA46658Y1034 J2... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,316 | -4,01 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - 8-K, Current Report | ||
| CARDIOL THERAPEUTICS | 0,906 | +2,84 % | Cardiol Therapeutics Inc. - 6-K, Report of foreign issuer | ||
| ATAIBECKLEY | 4,300 | -5,29 % | AtaiBeckley Inc.: AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder | 156 patients randomized in multi-center, double-blind, placebo-controlled Phase 2b Elumina trial; topline data anticipated in Q4 2026 (ClinicalTrials.gov: NCT06524830)AtaiBeckley plans to advance... ► Artikel lesen | |
| BIOMERIEUX | 69,85 | +0,36 % | Dividendenbekanntmachungen (09.06.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AMEREN CORPORATION US0236081024 0,75 USD 0,6501 EUR AMUNDI SA FR0004125920 - 4,25 EUR BECTON DICKINSON AND COMPANY US0758871091 1... ► Artikel lesen | |
| BIO GREEN MED SOLUTION | 0,800 | +0,63 % | Morning Market Movers: Bio Green Med Solution, Solidion Technology, Indaptus Therapeutics, Merlin, Inc. See Big Swings | BEIJING (dpa-AFX) - At 7:20 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ANAPTYSBIO | 55,92 | -3,82 % | AnaptysBio, Inc.: Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update | Completed spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations businessNow exclusively manages the financial collaborations for Jemperli with GSK and imsidolimab with VandaAnnounced... ► Artikel lesen | |
| GENUS | 23,400 | -2,50 % | Telekoms, Bau und Pharma: 32 Aktien gegen den KI-Kater: Berenbergs Rezept für nervöse Anleger | Rechenzentren werden gestrichen, Gesetze gegen KI häufen sich, die Bewertungen bleiben hoch. Berenberg zeigt, mit welchen 32 Aktien Anleger dem Tech-Trubel entkommen können.Die KI-Rallye war lange die... ► Artikel lesen | |
| MEIRAGTX | 11,500 | -4,96 % | MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec) | MeiraGTx to receive up to $375 million in non-dilutive cash and up to $25 million in equity investmentFollowing regulatory approval, Oberland Capital to receive low single-digit capped royalties on... ► Artikel lesen | |
| AKESO | 10,630 | -1,80 % | Akeso, Inc.: Ligufalimab (CD47)-Based Combination Achieves Deep Responses and Survival Benefit in Frontline AML: Phase II Results Presented in Oral Session at EHA 2026 | HONG KONG, June 17, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 2,360 | +2,61 % | XTL Biopharmaceuticals Ltd.: XTL Completed the Acquisition of Psyga Bio Ltd. | expands its IP portfolio to clinical-stage biopharmaceutical assets XTL Biopharmaceuticals (XTL) Completes the Acquisition of Psyga Bio and Establishes Psychedelic Biotechnology Platform At a historic... ► Artikel lesen | |
| ABIONYX PHARMA | 1,854 | +1,42 % | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| MAAT PHARMA | 2,675 | 0,00 % | MaaT Pharma Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen |
ISOFOL MEDICAL AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,060 Euro und damit +8,70 % im Plus. Aus der Ausschüttung der letzten 12 Monate von insgesamt 0,00 Euro errechnet sich eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISOFOL MEDICAL AB finden Sie auf Wallstreet Online.